Relief Therapeutics Holding SA (now MindMaze Therapeutics Holding SA) Overview
Pro stress-test →Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products, mainly developing drugs of natural human origin. In November 2025, shareholders approved a business combination between Relief and NeuroX Group SA to create a publicly listed, digital neurotherapeutics company combining NeuroX's brain health platform with Relief's specialty biopharmaceutical portfolio.
Strategic Profile
Pro stress-test →The company's development pipeline is focused on three main areas: rare genetic and metabolic disorders, rare connective tissue disorders, and rare lung diseases. With core expertise in drug delivery systems and drug repurposing, the clinical pipeline includes innovative treatments for rare dermatological, metabolic and respiratory conditions, with several approved products brought to market through licensing and distribution partnerships.
Competitive Landscape
Pro stress-test →Relief operates in the rare disease biopharmaceutical space alongside companies focused on niche therapeutic areas. Competitors include Santhera Pharmaceuticals Holding, Idorsia Pharmaceuticals, Genfit, DBV Technologies, and Marinomed Biotech. The merger with NeuroX's digital neurotherapeutics assets creates a differentiated platform combining pharmacology with AI-powered brain health technology.
Industry Context
Relief Therapeutics Holding SA (now MindMaze Therapeutics Holding SA) operates in Biopharmaceuticals / Digital Neurotherapeutics.
Key facts
Founded: 2013 · Headquarters: Geneva, Switzerland · Employees: N/A · Revenue: N/A · Market cap: $45.3M (January 2026)